blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2850433

EP2850433 - USE OF TROP-2 AS PREDICTIVE MARKER OF RESPONSE TO ANTI-TUMOR THERAPY BASED ON INHIBITORS OF AKT [Right-click to bookmark this link]
Former [2015/13]USE OF TROP-2 AS PREDICTIVE MARKER OF RESPONSE TO ANTI-TUMOR THERAPY BASED ON INHIBITORS OF CD9, AKT AND MOLECULES OF THE TETRASPANIN SIGNALLING NETWORK
[2018/10]
StatusNo opposition filed within time limit
Status updated on  21.06.2019
Database last updated on 15.06.2024
FormerThe patent has been granted
Status updated on  13.07.2018
FormerGrant of patent is intended
Status updated on  28.02.2018
FormerExamination is in progress
Status updated on  21.02.2017
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
ONCOXX Biotech s.r.l.
Via Garibaldi Vico XVII, 15
66034 Lanciano / IT
[2015/13]
Inventor(s)01 / GUERRA, Emanuela
Unità di Patologia Oncologica,c/o CeSI-MeT
Fondazione Università "G. D'Annunzio"
Via Polacchi 11
66100 Chieti (IT) / IT
02 / ALBERTI, Saverio
Unità di Patologia Oncologica, c/o CeSI-MeT
Fondazione Università "G. D'Annunzio"
Via Polacchi 11
66100 Chieti (IT) / IT
 [2018/33]
Former [2015/13]01 / GUERRA, Emanuela
Unità di Patologia Oncologica CeSI
Fondazione Università "G. D'Annunzio"
Via Colle dell'Ara
66100 Chieti Scalo (CH) / IT
02 / ALBERTI, Saverio
Unità di Patologia Oncologica CeSI
Fondazione Università "G. D'Annunzio"
Via Colle dell'Ara
66100 Chieti Scalo (CH) / IT
Representative(s)Statti, Francesco
Isea S.R.L.
Via G. Carducci, 6
62012 Civitanova Marche / IT
[2015/13]
Application number, filing date13739819.416.05.2013
[2018/33]
WO2013IT00139
Priority number, dateIT2012CH0000816.05.2012         Original published format: IT CH20120008
[2015/13]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2013171777
Date:21.11.2013
Language:EN
[2013/47]
Type: A2 Application without search report 
No.:EP2850433
Date:25.03.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 21.11.2013 takes the place of the publication of the European patent application.
[2015/13]
Type: B1 Patent specification 
No.:EP2850433
Date:15.08.2018
Language:EN
[2018/33]
Search report(s)International search report - published on:EP20.03.2014
(Supplementary) European search report - dispatched on:EP22.03.2016
ClassificationIPC:G01N33/574, A61P35/00, G01N33/50
[2018/10]
CPC:
G01N33/5748 (EP,CN,US); A61K31/4375 (US); A61K31/4985 (US);
A61K31/713 (US); A61K39/39558 (US); A61P35/00 (EP);
C07K16/30 (US); C12Q1/6886 (US); G01N33/5011 (US);
G01N33/5088 (US); C12Q2600/106 (US); G01N2333/82 (EP,CN,US);
G01N2500/04 (EP,CN,US); G01N2500/10 (US); G01N2800/52 (EP,CN,US) (-)
Former IPC [2015/13]G01N33/574, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/13]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VERWENDUNG VON TROP-2 ALS PRÄDIKTIVER MARKER DER REAKTION AUF EINE ANTITUMORTHERAPIE AUF GRUNDLAGE VON AKT-HEMMERN[2018/10]
English:USE OF TROP-2 AS PREDICTIVE MARKER OF RESPONSE TO ANTI-TUMOR THERAPY BASED ON INHIBITORS OF AKT[2018/10]
French:UTILISATION DE TROP-2 EN TANT QUE MARQUEUR PRÉDICTIF DE RÉPONSE À UNE THÉRAPIE ANTICANCÉREUSE À BASE D'INHIBITEURS D'AKT[2018/10]
Former [2015/13]VERWENDUNG VON TROP-2 ALS PRÄDIKTIVER MARKER DER REAKTION AUF EINE ANTITUMORTHERAPIE AUF GRUNDLAGE VON CD9- UND AKT-HEMMERN SOWIE MOLEKÜLE AUS DEM TETRASPANIN-SIGNALISIERUNGSNETZWERKS
Former [2015/13]USE OF TROP-2 AS PREDICTIVE MARKER OF RESPONSE TO ANTI-TUMOR THERAPY BASED ON INHIBITORS OF CD9, AKT AND MOLECULES OF THE TETRASPANIN SIGNALLING NETWORK
Former [2015/13]UTILISATION DE TROP-2 EN TANT QUE MARQUEUR PRÉDICTIF DE RÉPONSE À UNE THÉRAPIE ANTICANCÉREUSE À BASE D'INHIBITEURS DE CD9, AKT ET DE MOLÉCULES DU RÉSEAU DE SIGNALISATION DE LA TÉTRASPANINE
Entry into regional phase16.12.2014National basic fee paid 
16.12.2014Designation fee(s) paid 
16.12.2014Examination fee paid 
Examination procedure16.12.2014Examination requested  [2015/13]
15.07.2015Amendment by applicant (claims and/or description)
22.03.2016Despatch of a communication from the examining division to which search results under Rule 164(2) EPC are annexed (Time limit: M04) [2016/16]
22.03.2016Despatch of a communication from the examining division (Time limit: M04)
26.07.2016Reply to a communication from the examining division
24.02.2017Invitation to indicate the basis for amendments (Time limit: M01)
03.04.2017Reply to an invitation to indicate the basis for amendments
20.06.2017Despatch of a communication from the examining division (Time limit: M04)
20.10.2017Reply to a communication from the examining division
01.03.2018Communication of intention to grant the patent
04.07.2018Fee for grant paid
04.07.2018Fee for publishing/printing paid
04.07.2018Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  22.03.2016
Opposition(s)16.05.2019No opposition filed within time limit [2019/30]
Fees paidRenewal fee
01.06.2015Renewal fee patent year 03
31.05.2016Renewal fee patent year 04
31.05.2017Renewal fee patent year 05
01.06.2018Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU16.05.2013
AL15.08.2018
AT15.08.2018
CY15.08.2018
CZ15.08.2018
DK15.08.2018
EE15.08.2018
ES15.08.2018
FI15.08.2018
HR15.08.2018
IT15.08.2018
LT15.08.2018
LV15.08.2018
MC15.08.2018
MK15.08.2018
MT15.08.2018
NL15.08.2018
PL15.08.2018
RO15.08.2018
RS15.08.2018
SE15.08.2018
SI15.08.2018
SK15.08.2018
SM15.08.2018
TR15.08.2018
BG15.11.2018
NO15.11.2018
GR16.11.2018
IS15.12.2018
PT15.12.2018
[2022/31]
Former [2021/34]HU16.05.2013
AL15.08.2018
AT15.08.2018
CY15.08.2018
CZ15.08.2018
DK15.08.2018
EE15.08.2018
ES15.08.2018
FI15.08.2018
HR15.08.2018
IT15.08.2018
LT15.08.2018
LV15.08.2018
MC15.08.2018
MT15.08.2018
NL15.08.2018
PL15.08.2018
RO15.08.2018
RS15.08.2018
SE15.08.2018
SI15.08.2018
SK15.08.2018
SM15.08.2018
TR15.08.2018
BG15.11.2018
NO15.11.2018
GR16.11.2018
IS15.12.2018
PT15.12.2018
Former [2021/32]HU16.05.2013
AL15.08.2018
AT15.08.2018
CY15.08.2018
CZ15.08.2018
DK15.08.2018
EE15.08.2018
ES15.08.2018
FI15.08.2018
HR15.08.2018
IT15.08.2018
LT15.08.2018
LV15.08.2018
MC15.08.2018
NL15.08.2018
PL15.08.2018
RO15.08.2018
RS15.08.2018
SE15.08.2018
SI15.08.2018
SK15.08.2018
SM15.08.2018
TR15.08.2018
BG15.11.2018
NO15.11.2018
GR16.11.2018
IS15.12.2018
PT15.12.2018
Former [2021/26]AL15.08.2018
AT15.08.2018
CY15.08.2018
CZ15.08.2018
DK15.08.2018
EE15.08.2018
ES15.08.2018
FI15.08.2018
HR15.08.2018
IT15.08.2018
LT15.08.2018
LV15.08.2018
MC15.08.2018
NL15.08.2018
PL15.08.2018
RO15.08.2018
RS15.08.2018
SE15.08.2018
SI15.08.2018
SK15.08.2018
SM15.08.2018
TR15.08.2018
BG15.11.2018
NO15.11.2018
GR16.11.2018
IS15.12.2018
PT15.12.2018
Former [2020/29]AL15.08.2018
AT15.08.2018
CZ15.08.2018
DK15.08.2018
EE15.08.2018
ES15.08.2018
FI15.08.2018
HR15.08.2018
IT15.08.2018
LT15.08.2018
LV15.08.2018
MC15.08.2018
NL15.08.2018
PL15.08.2018
RO15.08.2018
RS15.08.2018
SE15.08.2018
SI15.08.2018
SK15.08.2018
SM15.08.2018
TR15.08.2018
BG15.11.2018
NO15.11.2018
GR16.11.2018
IS15.12.2018
PT15.12.2018
Former [2020/16]AL15.08.2018
AT15.08.2018
CZ15.08.2018
DK15.08.2018
EE15.08.2018
ES15.08.2018
FI15.08.2018
HR15.08.2018
IT15.08.2018
LT15.08.2018
LV15.08.2018
MC15.08.2018
NL15.08.2018
PL15.08.2018
RO15.08.2018
RS15.08.2018
SE15.08.2018
SI15.08.2018
SK15.08.2018
SM15.08.2018
TR15.08.2018
BG15.11.2018
NO15.11.2018
GR16.11.2018
IS15.12.2018
Former [2020/07]AL15.08.2018
AT15.08.2018
CZ15.08.2018
DK15.08.2018
EE15.08.2018
ES15.08.2018
FI15.08.2018
HR15.08.2018
IT15.08.2018
LT15.08.2018
LV15.08.2018
MC15.08.2018
NL15.08.2018
PL15.08.2018
RO15.08.2018
RS15.08.2018
SE15.08.2018
SI15.08.2018
SK15.08.2018
SM15.08.2018
BG15.11.2018
NO15.11.2018
GR16.11.2018
IS15.12.2018
Former [2019/37]AL15.08.2018
AT15.08.2018
CZ15.08.2018
DK15.08.2018
EE15.08.2018
ES15.08.2018
FI15.08.2018
HR15.08.2018
IT15.08.2018
LT15.08.2018
LV15.08.2018
NL15.08.2018
PL15.08.2018
RO15.08.2018
RS15.08.2018
SE15.08.2018
SI15.08.2018
SK15.08.2018
SM15.08.2018
BG15.11.2018
NO15.11.2018
GR16.11.2018
IS15.12.2018
Former [2019/26]AL15.08.2018
AT15.08.2018
CZ15.08.2018
DK15.08.2018
EE15.08.2018
ES15.08.2018
FI15.08.2018
HR15.08.2018
IT15.08.2018
LT15.08.2018
LV15.08.2018
NL15.08.2018
PL15.08.2018
RO15.08.2018
RS15.08.2018
SE15.08.2018
SK15.08.2018
SM15.08.2018
BG15.11.2018
NO15.11.2018
GR16.11.2018
IS15.12.2018
Former [2019/23]AL15.08.2018
AT15.08.2018
CZ15.08.2018
EE15.08.2018
ES15.08.2018
FI15.08.2018
HR15.08.2018
IT15.08.2018
LT15.08.2018
LV15.08.2018
NL15.08.2018
PL15.08.2018
RO15.08.2018
RS15.08.2018
SE15.08.2018
SK15.08.2018
BG15.11.2018
NO15.11.2018
GR16.11.2018
IS15.12.2018
Former [2019/22]AL15.08.2018
AT15.08.2018
CZ15.08.2018
FI15.08.2018
HR15.08.2018
IT15.08.2018
LT15.08.2018
LV15.08.2018
NL15.08.2018
PL15.08.2018
RO15.08.2018
RS15.08.2018
SE15.08.2018
BG15.11.2018
NO15.11.2018
GR16.11.2018
IS15.12.2018
Former [2019/21]AL15.08.2018
AT15.08.2018
FI15.08.2018
HR15.08.2018
IT15.08.2018
LT15.08.2018
LV15.08.2018
NL15.08.2018
RS15.08.2018
SE15.08.2018
BG15.11.2018
NO15.11.2018
GR16.11.2018
IS15.12.2018
Former [2019/12]AL15.08.2018
AT15.08.2018
FI15.08.2018
HR15.08.2018
LT15.08.2018
LV15.08.2018
NL15.08.2018
RS15.08.2018
SE15.08.2018
BG15.11.2018
NO15.11.2018
GR16.11.2018
IS15.12.2018
Former [2019/11]AT15.08.2018
FI15.08.2018
HR15.08.2018
LT15.08.2018
NL15.08.2018
RS15.08.2018
SE15.08.2018
BG15.11.2018
NO15.11.2018
GR16.11.2018
IS15.12.2018
Former [2019/10]AT15.08.2018
FI15.08.2018
LT15.08.2018
NL15.08.2018
RS15.08.2018
SE15.08.2018
BG15.11.2018
NO15.11.2018
GR16.11.2018
IS15.12.2018
Former [2019/09]FI15.08.2018
LT15.08.2018
NL15.08.2018
NO15.11.2018
IS15.12.2018
Former [2019/08]FI15.08.2018
LT15.08.2018
NO15.11.2018
IS15.12.2018
Former [2019/07]LT15.08.2018
Documents cited:Search[IY]WO2011130654  (GENENTECH INC [US], et al) [I] 1-10 * abstract * [Y] 1-10;
 [X]  - JOYCE VARUGHESE ET AL, "Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody", CANCER, (20110715), vol. 117, no. 14, doi:10.1002/cncr.25891, ISSN 0008-543X, pages 3163 - 3172, XP055057457 [X] 6 * abstract *

DOI:   http://dx.doi.org/10.1002/cncr.25891
 [X]  - JOYCE VARUGHESE ET AL, "Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody", AMERICAN JOURNAL OF OBSTETRICS & GYNECOLOGY, MOSBY, ST LOUIS, MO, US, vol. 205, no. 6, doi:10.1016/J.AJOG.2011.06.093, ISSN 0002-9378, (20110629), pages 567.e1 - 567.e7, (20110713), XP028116550 [X] 6 * abstract *

DOI:   http://dx.doi.org/10.1016/j.ajog.2011.06.093
 [X]  - JOYCE VARUGHESE ET AL, "High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody", GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS, LONDON, GB, vol. 122, no. 1, doi:10.1016/J.YGYNO.2011.03.002, ISSN 0090-8258, (20110303), pages 171 - 177, (20110310), XP028221428 [X] 6 * abstract *

DOI:   http://dx.doi.org/10.1016/j.ygyno.2011.03.002
 [X]  - RHODA RAJI ET AL, "Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody", JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, (20110101), vol. 30, no. 1, doi:10.1158/0008-5472.CAN-07-6135, ISSN 1756-9966, page 106, XP055052404 [X] 6 * abstract *

DOI:   http://dx.doi.org/10.1186/1756-9966-30-106
 [Y]  - M TREROTOLA ET AL, "Upregulation of Trop-2 quantitatively stimulates human cancer growth", ONCOGENE, (20110220), vol. 32, no. 2, doi:10.1038/onc.2012.36, ISSN 0950-9232, pages 222 - 233, XP055057442 [Y] 1-10 * abstract *

DOI:   http://dx.doi.org/10.1038/onc.2012.36
 [Y]  - ELIANA BIGNOTTI ET AL, "Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma", BMC CLINICAL PATHOLOGY, GB, (20120101), vol. 12, no. 1, doi:10.1186/1756-0500-5-65, ISSN 1472-6890, page 22, XP055255567 [Y] 1-10 * abstract *

DOI:   http://dx.doi.org/10.1186/1472-6890-12-22
 [I]  - JAU-CHEN LIN ET AL, "TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma", EMBO MOLECULAR MEDICINE, Weinheim, (20120315), vol. 4, no. 6, doi:10.1002/emmm.201200222, ISSN 1757-4676, pages 472 - 485, XP055255417 [I] 1-10 * abstract *

DOI:   http://dx.doi.org/10.1002/emmm.201200222
International search[A]WO2011085276  (WEISS GLEN, et al) [A] 1-6,8,10 * abstract *;
 [A]CA2798778  (LIVTECH INC [JP]) [A] 1-6,8,10 * page 41 - page 43 *;
 [A]  - VARUGHESE JOYCE ET AL, "Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody.", CANCER 15 JUL 2011, (20110715), vol. 117, no. 14, ISSN 1097-0142, pages 3163 - 3172, XP055057457 [A] 1-6,8,10 * abstract *

DOI:   http://dx.doi.org/10.1002/cncr.25891
 [A]  - VARUGHESE JOYCE ET AL, "Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody.", AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY DEC 2011, (201112), vol. 205, no. 6, ISSN 1097-6868, pages 567.e1 - 7, XP028116550 [A] 1-6,8,10 * abstract *

DOI:   http://dx.doi.org/10.1016/j.ajog.2011.06.093
 [A]  - VARUGHESE JOYCE ET AL, "High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody.", GYNECOLOGIC ONCOLOGY JUL 2011, (201107), vol. 122, no. 1, ISSN 1095-6859, pages 171 - 177, XP028221428 [A] 1-6,8,10 * abstract *

DOI:   http://dx.doi.org/10.1016/j.ygyno.2011.03.002
 [A]  - RAJI RHODA ET AL, "Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody.", JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH : CR 2011, (2011), vol. 30, ISSN 1756-9966, page 106, XP055052404 [A] 1-6,8,10 * abstract *

DOI:   http://dx.doi.org/10.1186/1756-9966-30-106
 [A]  - TREROTOLA M ET AL, "Upregulation of Trop-2 quantitatively stimulates human cancer growth.", ONCOGENE 10 JAN 2013, (20120220), vol. 32, no. 2, ISSN 1476-5594, pages 222 - 233, XP055057442 [A] 1-6,8,10 * the whole document *

DOI:   http://dx.doi.org/10.1038/onc.2012.36
 [A]  - NAKASHIMA KAZUE ET AL, "Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma.", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER 20 DEC 2004, (20041220), vol. 112, no. 6, ISSN 0020-7136, pages 1029 - 1035, XP002694347 [A] 1-6,8,10 * abstract *

DOI:   http://dx.doi.org/10.1002/ijc.20517
 [A]  - HUAYI HUANG ET AL, "Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20050615), vol. 11, no. 12, doi:10.1158/1078-0432.CCR-04-2107, ISSN 1078-0432, pages 4357 - 4364, XP008128315 [A] 1-6,8,10 * page 4363, column 2, paragraph 3 *

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-04-2107
Examination   - ELIANA BIGNOTTI ET AL, "Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma", BMC CLINICAL PATHOLOGY, GB, (20120101), vol. 12, no. 1, doi:10.1186/1756-0500-5-65, ISSN 1472-6890, page 22, XP055255567

DOI:   http://dx.doi.org/10.1186/1472-6890-12-22
    - JAU-CHEN LIN ET AL, "TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma", EMBO MOLECULAR MEDICINE, Weinheim, (20120315), vol. 4, no. 6, doi:10.1002/emmm.201200222, ISSN 1757-4676, pages 472 - 485, XP055255417

DOI:   http://dx.doi.org/10.1002/emmm.201200222
by applicant   - ALBERTI, S., "HIKE, a candidate protein binding site for PH domains, is a major regulatory region of Gbeta proteins.", PROTEINS, (1999), vol. 35, pages 360 - 363
    - ALBERTI, S.; S. MIOTTI ET AL., "Biochemical characterization of Trop-2, a cell surface molecule expressed by human carcinomas: formal proof that the monoclonal antibodies T16 and MOv-16 recognize Trop-2.", HYBRIDOMA, (1992), vol. 11, pages 539 - 5
    - ALBERTI, S.; M. NUTINI ET AL., "DNA methylation prevents the amplification of TROPI, a tumor associated cell surface antigen gene", PROC. NATL. ACAD. SCI. USA, (1994), vol. 91, pages 5833 - 7
    - BALZAR, M.; I. H. BRIAIRE-DE BRUIJN ET AL., "Epidermal growth factor-like repeats mediate lateral and reciprocal interactions of Ep-CAM molecules in homophilic adhesions.", MOL. CELL. BIOL., (2001), vol. 21, no. 7, doi:doi:10.1128/MCB.21.7.2570-2580.2001, pages 2570 - 80, XP055101614

DOI:   http://dx.doi.org/10.1128/MCB.21.7.2570-2580.2001
    - BARREIRO, O.; M. ZAMAI ET AL., "Endothelial adhesion receptors are recruited to adherent leukocytes by inclusion in preformed tetraspanin nanoplatforms.", J CELL BIOL, (2008), vol. 183, no. 3, pages 527 - 42
    - BASU, A.; D. M. GOLDENBERG ET AL., "The epithelial/carcinoma antigen EGP-1, recognized by monoclonal antibody RS7-3G11, is phosphorylated on serine 303.", INT. J. CANCER, (1995), vol. 62, doi:doi:10.1002/ijc.2910620419, pages 472 - 479, XP009098359

DOI:   http://dx.doi.org/10.1002/ijc.2910620419
    - BROWN, W. J.; M. G. FARQUHAR, "Immunoperoxidase methods for the localization of antigens in cultured cells and tissue sections by electron microscopy.", METHODS CELL BIOL, (1989), vol. 31, pages 553 - 69
    - BRUMMELKAMP, T. R.; R. BERNARDS ET AL., "A System for Stable Expression of Short Interfering RNAs in Mammalian Cells.", SCIENCE, (2002), vol. 296, no. 5567, doi:doi:10.1126/science.1068999, pages 550 - 553, XP002626048

DOI:   http://dx.doi.org/10.1126/science.1068999
    - CHALK, A. M.; C. WAHLESTEDT ET AL., "Improved and automated prediction of effective siRNA.", BIOCHEM BIOPHYS RES COMMUN, (2004), vol. 319, no. 1, doi:doi:10.1016/j.bbrc.2004.04.181, pages 264 - 74, XP004509878

DOI:   http://dx.doi.org/10.1016/j.bbrc.2004.04.181
    - CHONG, J. M.; D. W. SPEICHER, "Determination of Disulfide Bond Assignments and N-Glycosylation Sites of the Human Gastrointestinal Carcinoma Antigen GA733-2 (C017-lA, EGP, KSI-4, KSA, and Ep-CAM).", J. BIOL. CHEM., (2001), vol. 276, no. 8, pages 5804 - 5813
    - CICCARELLI, F.; A. ACCIARITO ET AL., "Large and diverse numbers of human diseases with HIKE mutations.", HUM. MOL. GENET., (2000), vol. 9, doi:doi:10.1093/hmg/9.6.1001, pages 1001 - 7, XP002213878

DOI:   http://dx.doi.org/10.1093/hmg/9.6.1001
    - CUBAS, R.; S. ZHANG ET AL., "Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway.", MOL CANCER, (2010), vol. 9, no. 1, doi:doi:10.1186/1476-4598-9-253, page 253, XP021077991

DOI:   http://dx.doi.org/10.1186/1476-4598-9-253
    - EL SEWEDY, T.; M. FORNARO ET AL., "Cloning of the murine Trop2 gene: conservation of a PIP2-binding sequence in the cytoplasmic domain of Trop-2.", INT J CANCER, (1998), vol. 75, no. 2, doi:doi:10.1002/(SICI)1097-0215(19980119)75:2<324::AID-IJC24>3.0.CO;2-B, pages 324 - 30, XP000929390

DOI:   http://dx.doi.org/10.1002/(SICI)1097-0215(19980119)75:2<324::AID-IJC24>3.0.CO;2-B
    - ELBASHIR, S. M.; J. HARBORTH ET AL., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.", NATURE, (2001), vol. 411, no. 6836, doi:doi:10.1038/35078107, pages 494 - 8, XP002529540

DOI:   http://dx.doi.org/10.1038/35078107
    - FORNARO, M.; R. DELL'ARCIPRETE ET AL., "Cloning of the gene encoding TROP-2, a cell-surface glycoprotein expressed by human carcinomas.", INT. J. CANCER, (1995), vol. 62, doi:doi:10.1002/ijc.2910620520, pages 610 - 8, XP000925819

DOI:   http://dx.doi.org/10.1002/ijc.2910620520
    - FREELEY, M.; J. PARK ET AL., "Loss of PTEN expression does not contribute to PDK-1 activity and PKC activation-loop phosphorylation in Jurkat leukaemic T cells.", CELL SIGNAL, (2007), vol. 19, no. 12, doi:doi:10.1016/j.cellsig.2007.07.020, pages 2444 - 57, XP022289757

DOI:   http://dx.doi.org/10.1016/j.cellsig.2007.07.020
    - GIULIETTI, A.; L. OVERBERGH ET AL., "An overview of real-time quantitative PCR: applications to quantify cytokine gene expression.", METHODS, (2001), vol. 25, no. 4, doi:doi:10.1006/meth.2001.1261, pages 386 - 401, XP002272122

DOI:   http://dx.doi.org/10.1006/meth.2001.1261
    - GUERRA, E.; M. TREROTOLA ET AL., "A bi-cistronic CYCLIN D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer.", CANCER RES, (2008), vol. 68, no. 19, pages 8113 - 8121
    - HAKOMORI, S. 1., "Inaugural Article: The glycosynapse.", PROC NATL ACAD SCI USA, (2002), vol. 99, no. 1, pages 225 - 32
    - HEMLER, M. E., "Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain.", ANNU REV CELL DEV BIOL, (2003), vol. 19, pages 397 - 422
    - JACINTO, E.; V. FACCHINETTI ET AL., "SfNI/MIPI maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity.", CELL, (2006), vol. 127, no. 1, pages 125 - 37
    - KLEIN, C. E.; B. HARTMANN ET AL., "Expression of 38-kD cell-surface glycoprotein in transformed human keratinocyte cell lines, basal cell carcinomas, and epithelial germs.", J. INVEST. DERMATOL., (1990), vol. 95, pages 74 - 82
    - KOUL, D.; R. SHEN ET AL., "Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma.", MOL CANCER THER, (2005), vol. 4, no. 11, pages 1681 - 8
    - LE NAOUR, F.; M. ANDRE ET AL., "Membrane microdomains and proteomics: lessons from tetraspanin microdomains and comparison with lipid rafts.", PROTEOMICS, (2006), vol. 6, no. 24, pages 6447 - 54
    - LEVY, S.; T. SHOHAM, "The tetraspanin web modulates immune- signalling complexes.", NAT REV IMMUNOL, (2005), vol. 5, no. 2, doi:doi:10.1038/nri1548, pages 136 - 48, XP055418748

DOI:   http://dx.doi.org/10.1038/nri1548
    - LINNENBACH, A. J.; B. A. SENG ET AL., "Retroposition in a family of carcinoma-associated antigen genes.", MOL. CELL. BIOL., (1993), vol. 13, pages 1507 - 1515
    - LIVAK, K. J.; T. D. SCHMITTGEN, "Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.", METHODS, (2001), vol. 25, no. 4, pages 402 - 8
    - MINGUEZ, P.; S. GOTZ ET AL., "SNOW, a web-based tool for the statistical analysis of protein-protein interaction networks.", NUCLEIC ACIDS RES, (2009), vol. 37, pages W 109 - 14
    - NAQUET, P.; H. LEPESANT ET AL., "Establishment and characterization of mouse thymic epithelial cell lines.", THYMUS, (1989), vol. 13, no. 3-4, pages 217 - 26
    - PAREKH, D. B.; W. ZIEGLER ET AL., "Multiple pathways control protein kinase C phosphorylation.", EMBO J, (2000), vol. 19, no. 4, pages 496 - 503
    - POLISHCHUK, R. S.; E. V. POLISHCHUK ET AL., "Correlative light-electron microscopy reveals the saccular-tabular ultrastructure of carriers operating between the Golgi apparatus and the plasma membrane.", J. CELL BIOL., (2000), vol. 148, pages 45 - 58
    - ROSSE, C.; M. LINCH ET AL., "PKC and the control of localized signal dynamics.", NAT REV MOL CELL BIOL, (2010), vol. 11, no. 2, doi:doi:10.1038/nrm2847, pages 103 - 12, XP009173519

DOI:   http://dx.doi.org/10.1038/nrm2847
    - ROSSI, C.; A. DI LENA ET AL., "Intestinal tumour chemoprevention with the antioxidant lipoic acid stimulates the growth of breast cancer.", EUR J CANCER, (2008), vol. 44, doi:doi:10.1016/j.ejca.2008.08.021, pages 2696 - 2704, XP025632381

DOI:   http://dx.doi.org/10.1016/j.ejca.2008.08.021
    - SARBASSOV, D. D.; D. A. GUERTIN ET AL., "Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.", SCIENCE, (2005), vol. 307, no. 5712, doi:doi:10.1126/science.1106148, pages 1098 - 101, XP002379044

DOI:   http://dx.doi.org/10.1126/science.1106148
    - SEMIZAROV, D.; L. FROST ET AL., "Specificity of short interfering RNA determined through gene expression signatures.", PROC NATL ACAD SCI USA, (2003), vol. 100, no. 11, doi:doi:10.1073/pnas.1131959100, pages 6347 - 52, XP002316495

DOI:   http://dx.doi.org/10.1073/pnas.1131959100
    - TREROTOLA, M.; P. CANTANELLI ET AL., "Up-regulation of Trop-2 quantitatively stimulates human cancer growth.", ONCOGENE, (2013), vol. 32, pages 222 - 233
    - TREROTOLA, M.; S. RATHORE ET AL., "CD133, Trop-2 and alpha2betal integrin surface receptors as markers of putative human prostate cancer stem cells.", AM J TRANSL RES, (2010), vol. 2, no. 2, pages 135 - 44
    - WANG, J.; R. DAY ET AL., "Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers.", MOL CANCER THER, (2008), vol. 7, no. 2, doi:doi:10.1158/1535-7163.MCT-07-2003, pages 280 - 5, XP002541438

DOI:   http://dx.doi.org/10.1158/1535-7163.MCT-07-2003
    - WEN, H. C.; W. C. HUANG ET AL., "Negative regulation of phosphatidylinositol 3-kinase and Akt signalling pathway by PKC.", CELL SIGNAL, (2003), vol. 15, no. 1, pages 37 - 45
    - ZHANG, X. A.; A. L. BONTRAGER ET AL., "Transmembrane-4 superfamily proteins associate with activated protein kinase C (PKC) and link PKC to specific beta(l) integrins.", J BIOL CHEM, (2001), vol. 276, no. 27, pages 25005 - 13
 WO2009IT00035
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.